GLPwatch
Cagrilintide
Pipeline · Long-acting amylin analogue
Last updated 2026-07-12Cagrilintide is a long-acting drug designed to mimic amylin, a natural hormone in the body that helps control blood sugar and appetite. It is being developed as a potential treatment for obesity and related conditions, though it has not yet been approved for any specific use.
AI summary of the sources below.
| Mechanism | Long-acting amylin analogue A long-acting copy of amylin, a hormone that curbs appetite and slows stomach emptying. |
|---|---|
| Status | Pipeline |
| Branded products | — (none approved) |
| Manufacturer(s) | novo-nordisk |
How Cagrilintide connects
- Maker Novo Nordisk
- Trials 19 trials
- Research 34 papers
Trials (19)
- Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide
- A Research Study to Compare Blood Levels of Two Different Versions of Cagrilintide in Adults With Excess Body Weight
- A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor
- Weight Loss in People Living With Overweight or Obesity Following Treatment With Cagrilintide
- Evaluation of the Tolerability of Cagrilintide in Participants Not Tolerating GLP-1-RA Therapies Due to Gastrointestinal Adverse Events
- A Research Study to Compare Blood Levels of Cagrilintide and Semaglutide After Combined Versus Separate Injections in People With Overweight or Obesity
- A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
- Research Study to Look at How Well Cagrilintide Together With Semaglutide Works in People With Type 2 Diabetes
- A Study to See How Metabolism is Influenced by Weight Loss Due to Intervention With Cagrilintide and Semaglutide Compared to Diet
- Investigating How CagriSema, Semaglutide and Cagrilintide Regulate Insulin Effects in the Body of People With Type 2 Diabetes
- A Research Study Looking at How a Single Dose of the Medicine Cagrilintide Works in Participants With Reduced Liver Function and in Healthy Participants With Normal Liver Function and How Cagrilintide is Absorbed and Used by the Body
- The Role of the Amylin Analogue Cagrilintide in Bone Metabolism
- A Research Study to Compare Blood Levels of Cagrilintide and Semaglutide After Single Doses of Different Versions of Injectable CagriSema in Adults With Overweight or Obesity
- A Research Study Looking at How Cagrilintide Works on the Heart Rhythm in Healthy Participants
- A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and Placebo
- A Research Study Looking Into How Cagrilintide Influences Food Intake and Appetite in People With Overweight or Obesity
- Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscle Health)
- A Research Study to Compare Blood Levels of Cagrilintide After Multiple Doses of Different Versions of Cagrilintide in Adults With Overweight or Obesity
- Effects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver Disease
Top research (34)
- Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial.
- Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial.
- Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial.
- Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity.
- Development of Cagrilintide, a Long-Acting Amylin Analogue.
- Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes.
- Does receptor balance matter? - Comparing the efficacies of the dual amylin and calcitonin receptor agonists cagrilintide and KBP-336 on metabolic parameters in preclinical models.
- Cagrilintide: A Long-Acting Amylin Analog for the Treatment of Obesity.
- Cagrilintide plus semaglutide for obesity management.
- Cagrilintide lowers bodyweight through brain amylin receptors 1 and 3.
- Structural and dynamic features of cagrilintide binding to calcitonin and amylin receptors.
- Efficacy and Safety of Cagrilintide Alone and in Combination with Semaglutide (Cagrisema) as Anti-Obesity Medications: A Systematic Review and Meta-Analysis.
- A Cross-Species Atlas of the Dorsal Vagal Complex Reveals Neural Mediators of Cagrilintide's Effects on Energy Balance.
- Cagrilintide is not associated with clinically relevant QTc prolongation: A thorough QT study in healthy participants.
- Comparative Effectiveness of CagriSegma, Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta-Analysis of Randomized Clinical Trials.
- Efficacy and safety of co-administered cagrilintide and semaglutide versus semaglutide alone in adults with overweight or obesity with or without type 2 diabetes in Japan and Taiwan (REDEFINE 5): a multicentre, randomised, active-controlled, phase 3a trial.
- In adults with overweight or obesity, weekly subcutaneous cagrilintide-semaglutide increased weight loss at 68 wk.
- Characterization of 0839 - A tool compound for pre-clinical mode-of-action studies of amylin analogues such as cagrilintide.
- Efficacy and Safety of Cagrilintide and Cagrisema Versus Semaglutide as Anti-Obesity Medications: A Systematic Review, Meta-Analysis and Meta-Regression.
- Cagrilintide-Semaglutide in Adults with Overweight or Obesity.
- Structural and mechanistic insights into dual activation of cagrilintide in amylin and calcitonin receptors.
- Cagrilintide-Semaglutide in Adults with Overweight or Obesity.
- Cagrilintide and CagriSema for weight reduction and metabolic risk modification in overweight or obesity: a systematic review and meta-analysis.
- Cagrilintide-Semaglutide in Adults with Overweight or Obesity. Reply.
- Cagrilintide-Semaglutide in Adults with Overweight or Obesity.